Rafarma Pharmaceuticals Stock Performance
| RAFA Stock | USD 0.16 0.02 14.29% |
Rafarma Pharmaceuticals holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -2.62, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Rafarma Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Rafarma Pharmaceuticals is expected to outperform it. Use Rafarma Pharmaceuticals treynor ratio, downside variance, and the relationship between the total risk alpha and value at risk , to analyze future returns on Rafarma Pharmaceuticals.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Rafarma Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent technical and fundamental indicators, Rafarma Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Rafarma |
Rafarma Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 8.40 in Rafarma Pharmaceuticals on December 5, 2024 and sell it today you would earn a total of 7.60 from holding Rafarma Pharmaceuticals or generate 90.48% return on investment over 90 days. Rafarma Pharmaceuticals is currently generating 1.7282% in daily expected returns and assumes 11.7091% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Rafarma, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rafarma Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rafarma Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Rafarma Pharmaceuticals, and traders can use it to determine the average amount a Rafarma Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1476
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | RAFA | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.71 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.73 actual daily | 34 66% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Rafarma Pharmaceuticals is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rafarma Pharmaceuticals by adding it to a well-diversified portfolio.
Rafarma Pharmaceuticals Fundamentals Growth
Rafarma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rafarma Pharmaceuticals, and Rafarma Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rafarma Pink Sheet performance.
| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.88) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 7.89 M | |||
| Price To Earning | (1.29) X | |||
| Price To Sales | 857.77 X | |||
| Book Value Per Share | 40.49 X | |||
| Cash Flow From Operations | (1 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 460.33 M | |||
| Retained Earnings | (2.38 M) | |||
| Current Liabilities | 292 K | |||
About Rafarma Pharmaceuticals Performance
By analyzing Rafarma Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Rafarma Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Rafarma Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rafarma Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Rafarma Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rafarma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rafarma Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rafarma Pharmaceuticals is way too risky over 90 days horizon | |
| Rafarma Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Rafarma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Rafarma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (14.85 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rafarma Pharmaceuticals generates negative cash flow from operations |
- Analyzing Rafarma Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rafarma Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rafarma Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rafarma Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rafarma Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rafarma Pharmaceuticals' pink sheet. These opinions can provide insight into Rafarma Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Rafarma Pink Sheet analysis
When running Rafarma Pharmaceuticals' price analysis, check to measure Rafarma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rafarma Pharmaceuticals is operating at the current time. Most of Rafarma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rafarma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rafarma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rafarma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |